regardless of encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. These insurers are often building obstacles to reimbursement, like steep expense requirements and PA that restrict consumer availability. Industry indicate that the